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Background: Despite supplementation with standard multivitamins and pancreatic enzymes, deficiencies of vitamins D and K and antioxidants are
common in cystic fibrosis (CF).
Methods: In this non-randomized, open-label study, AquADEKs® softgels were given daily over 12 weeks to 14 CF subjects (mean age 15 years,
range 10–23) without a preceding wash-out period. Both pancreatic sufficient and insufficient subjects were enrolled. Plasma vitamin and
antioxidant levels, urine 8-isoprostane levels, anthropometric measures, and pulmonary function were determined at baseline, 6 and 12 weeks.
Results: Daily supplementation significantly increased plasma beta(β)-carotene, coenzyme Q10, and γ-tocopherol concentrations, decreased
proteins induced in vitamin K absence (PIVKA-II) levels, but did not normalize vitamin D and K status in all subjects. Vitamin A levels did not
exceed the normal range for any subject during the entire study period. Modest improvements in weight percentile and pulmonary function were
observed. Change in plasma β-carotene concentrations weakly correlated with changes in weight and body mass index percentiles.
Conclusions: In this study, AquADEKs® increased systemic antioxidant levels, while maintaining vitamin A levels in the normal range, and
improved but did not completely normalize vitamin D and K status. Increased β-carotene levels were associated with improved growth
parameters. These results warrant further clinical evaluation in CF.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antioxidants; Vitamins; Oxidative stress; Cystic fibrosis1. Introduction
Pancreatic insufficiency and a diminished bile acid pool
cause malabsorption of important fat-soluble nutrients and
antioxidants including beta(β)-carotene, coenzyme Q10Abbreviations: CF, cystic fibrosis; CoQ10, coenzyme Q10; PIVKA-II,
proteins induced in vitamin K absence; FEV1, forced expiratory volume in 1 s;
FE-1, fecal elastase-1; BMI, body mass index; LLD, lower limit of detection.
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fibrosis (CF). Fat-soluble vitamin supplementation is standard
clinical practice in CF [1]. Despite supplementation with
standard multivitamins and pancreatic enzymes, deficiencies of
vitamins D and K and antioxidants have been repeatedly
demonstrated in individuals with CF, particularly in those with
pancreatic insufficiency [2–10]. These antioxidant deficiencies
may impair lung host defenses and contribute to oxidative
damage in CF [11,12]. Optimizing fat-soluble vitamin and
antioxidant status in CF is an important clinical goal and may
influence health outcomes.
An emerging concern is excess vitamin intake and risk for
toxicity, particularly related to vitamin A. Two studies reported
elevated vitamin A intake and increased serum retinol concentra-
tions in CF [13,14]. Vitamin A toxicity has been previously
documented in CF [15]. Therefore, long-term daily supplemen-
tation with CF-specific multivitamins containing retinol requires
monitoring to prevent both deficiency and toxicity [10].d by Elsevier B.V. All rights reserved.
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of fat-soluble nutrients and antioxidants in liquid form safely
and effectively increased the plasma levels of these important
compounds in 10 pancreatic insufficient (PI) subjects with
CF [16]. In this pilot study, we did not observe elevated
vitamin levels or toxicity. However, the lack of potentially
toxic levels may have been related to an initial wash-out
period which allowed vitamin levels to fall prior to treatment
and a relatively short treatment period. Further, we did not
enroll pancreatic sufficient (PS) subjects, in whom the risk for
toxicity is theoretically higher due to their superior absorption
compared with PI subjects. Because of these limitations, it
was deemed prudent to further evaluate the tolerability of
this supplement and confirm that the blood levels of fat-
soluble vitamins, specifically vitamin A, do not exceed nor-
mal ranges.
The purpose of this study was to further evaluate the final
commercial formulation in softgel capsule form (AquADEKs®,
Yasoo Health Inc.), administered daily for 12 weeks without a
preceding wash-out period, in both PS and PI CF subjects.
We hypothesized that this supplement would safely increase
circulating levels of β-carotene, CoQ10, and γ-tocopherol,
decrease levels of proteins induced in vitamin K absence
(PIVKA-II; surrogate of vitamin K status), and maintain
vitamin A and D concentrations in the normal range.
Furthermore, growth indices, lung function and urinary 8-
isoprostane levels, a marker of oxidative stress, were measured
in order to examine potential clinical and antioxidant benefits of
this formulation.Table 1
AquADEKs® composition (1 softgel capsule).
Compound Amount
per softgel
% Daily value a
Vitamin A (92% β-carotene and 8% palmitate) 18,167 IU 363
Vitamin C (as sodium ascorbate) 75 mg 125
Vitamin D3 (as cholecalciferol) 800 IU 200
Vitamin E (as α-tocopherol) 150 IU 500
Vitamin E (other mixed tocopherols) 80 mg **
Vitamin K1 (as phytonadione) 700 mcg 875
Coenzyme Q10 10 mg **
Thiamin (Vitamin B1) 1.5 mg 100
Riboflavin (Vitamin B2) 1.7 mg 100
Niacin (as niacinamide) 10 mg 50
Vitamin B6 (as pyridoxine hydrochloride) 1.9 mg 95
Folic acid 200 mcg 50
Vitamin B12 (as cyanocobalamin) 12 mcg 200
Biotin 100 mcg 33
Pantothenic acid (as calcium d-pantothenate) 12 mg 120
Zinc (as zinc sulfate) 10 mg 67
Selenium (as selenomethionine) 75 mcg 107
** Daily value not established for these nutrients.
a Percent daily values based on a 2000 calorie diet.2. Methods
2.1. Subjects
Seventeen subjects with CF were recruited from the Pediatric
CF Center at The Children's Hospital and University of
Colorado Denver School of Medicine. Inclusion criteria were
ages greater than 10 years, weight greater than 30 kg, forced
expiratory volume in 1 s (FEV1) greater than 35% of predicted,
and stable pulmonary disease as defined by both clinical
impression and no hospitalizations in the 30 days prior to
screening. Subjects were excluded if they were pregnant or
lactating, had significant liver disease as defined by clinical
findings of portal hypertension or cirrhosis or liver enzymes
greater than twice the upper limits of normal, had oral
supplementation with AquADEKs® or another source of β-
carotene or CoQ10 in the 2 months prior to the study, or had
participated in another interventional clinical trial within
30 days of screening. Eleven subjects were PI as documented
by a spot fecal elastase-1 (FE-1)≤100 μg/g in a stool sample at
the screening visit and 6 subjects were PS based on a FE-1
N100 μg/g in this screening stool sample [17].
The protocol was approved by the Colorado Multiple
Institutional Review Board and the Pediatric Clinical Transla-
tional Research Center. Informed consent was obtained from
each of the subjects and/or their parents.2.2. Study design
This was a prospective, non-randomized, open-label trial of
AquADEKs® given once daily over 12 weeks. Each partici-
pant came to clinic for 3 study visits at 0 (baseline), 6 and
12 weeks. At the baseline visit, subjects underwent a physical
examination including anthropometric measurements, fasting
blood draw for vitamin and nutrient levels, urine pregnancy
test for females of childbearing age, urine sample for 8-
isoprostanes, stool sample for FE-1, and spirometry. Weight
for age and body mass index (BMI) percentiles were calculated
using the 2000 Centers for Disease Control Growth Charts
for the United States. Percentiles for the four subjects over
20 years of age were calculated using the percentile curves at
age 20. The subjects were instructed to discontinue any
supplemental doses of vitamins including those specific to CF
such as ADEK®, SourceCF® and Vitamax®, but to continue
all other medications unchanged. Subjects were given a three
month supply of AquADEKs®, instructed to take 2 softgels
daily with their enzymes immediately prior to breakfast, and
document the date and time of dosing on a self-reported study
medication diary. The composition of AquADEKs® is detailed
in Table 1.
At visits 2 (6 weeks) and 3 (12 weeks), subjects were
asked about adverse effects possibly related to the formula-
tion including flushing, nausea, vomiting, abdominal pain,
anorexia, irritability, drowsiness, altered mental status, ataxia,
and myalgias. Subjects were also monitored for worsening
respiratory symptoms, medication changes, and hospitaliza-
tions. At these visits, an abbreviated physical examination
including anthropometrics was performed, fasting blood was
again obtained for vitamin and nutrient levels (subjects were
instructed not to ingest vitamin supplementation the day of
the study visits), spirometry was repeated, and the remaining
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repeat urine sample for 8-isoprostanes was collected at visit
3.2.3. Laboratory assays
2.3.1. Vitamins and antioxidants
Subjects were asked to fast for at least 8 h prior to having their
blood specimens drawn. Whole blood was collected into EDTA
tubes and centrifuged at 3000 rpm for 5 min. Specimens were
protected from light and the plasma was removed and frozen
at −70 °C. Plasma was assayed for retinol, α- and γ-tocopherol,
β-carotene, and CoQ10 in the Pediatric Clinical Translational
Research Center Core Laboratory at The Children's Hospital
using a validated high performance liquid chromatography
method [18]. 25-Hydroxyvitamin D in plasma was measured
with the use of an FDA-approved radioimmunoassay kit
(DiaSorin, Stillwater, MN). Plasma was also sent to Esoterix
Inc. laboratory services (Englewood, CO) where PIVKA-II was
determined by a commercially-available ELISA kit (Diagnostica
Stago, Parsippany, NJ). The laboratory's reference range for
vitamin A (retinol) is 19–77 μg/dL, vitamin D (25-hydroxy)
is 30–100 ng/mL, vitamin E (α-tocopherol) is 3.8–20.3 μg/mL,
γ-tocopherol is 0.4–4.0 μg/mL, β-carotene is 0.04–0.85 μg/mL,
CoQ10 is 0.29–0.89 μg/mL, and PIVKA-II is ≤3 ng/mL. The
lower limits of detection for the relevant assays were: β-carotene,
0.03 μg/mL; γ-tocopherol, 1.0 μg/mL; and PIVKA-II, 2 ng/mL.2.3.2. 8-Isoprostanes
Subjects provided urine samples in sterile specimen collec-
tion cups. Urine samples were processed, frozen at −70 °C, and
later assayed for 8-isoprostane using a commercially-available
ELISA kit (Cayman Chemical, Ann Arbor, MI). The detection
limit was 2.7 pg/mL; the IC50 (concentration required to inhibit
initial binding by 50%) was 10 pg/mL.2.3.3. Pulmonary function testing
Spirometry was performed according to American Thoracic
Society guidelines. Functional indices included FEV1, forced
vital capacity (FVC), and mid-volume forced expiratory flows
(FEF25–75). All spirometric values are expressed as percent of
predicted normal using reference equations [19].Table 2





Gender (male:female) 5:6 2:4
Age (years) 15.5±4.6 15.0±3.8
Weight (kg) 48.7±10.1 50.8±14.3
Weight (percentile) 39.0±26.9 52.5±25.5
BMI (percentile) 36.6±26.6 56.7±20.8
FEV1 (% predicted) 89.5±27.7 95.5±6.7
Fecal elastase (μg/g) Allb15 (LLD of assay) AllN450
BMI, body mass index; FEV1, forced expiratory volume in 1 s; and LLD, lower
limit of detection.
⁎ Values are mean±standard deviation.2.4. Statistical analysis
Data were analyzed using SAS v9.2 (SAS Institute Inc.,
Cary, NC, USA). Statistical comparisons were performed using
a non-parametric Wilcoxon signed rank test for paired data
(change in values from baseline to visit 3). Wilcoxon ranked
sum test was used to compare independent pancreatic status
groups. Relationships between changes in plasma antioxidants
and clinical outcome variable were studied by Spearman's rank
correlation coefficient for non-parametric data. Data are
presented as median and interquartile (IQR) range. Differences
were considered statistically significant at pb0.05.3. Results
Of the 17 CF subjects initially enrolled, 14 fully completed
the study. One PS subject withdrew from the study after one
week of therapy due to adverse events (nausea, abdominal pain,
and headache) that preceded study enrollment but may have
been exacerbated by the formulation. A second PS subject was
withdrawn between visits 2 and 3 at the discretion of a nurse
unfamiliar with this study because of symptoms that were
eventually judged to be unrelated to the formulation. A third PS
subject was withdrawn after visit 2 in order to become eligible
for another investigational trial. Compliance with taking the
study formulation, as assessed by pill counts at visits 2 and 3,
was greater than 90% in 11 of the 14 subjects who fully
completed the study. The baseline clinical characteristics of all
17 subjects are presented in Table 2. The average age of study
participants was 15 years (range 10–23 years). All PI subjects
had a FE-1 b15 μg/g while PS subjects were all above 450 μg/g.
Overall, the tolerability of this formulation was satisfactory.
Two subjects withdrew from the study for adverse events as
described above. In the remaining 14 subjects, a total of 58
adverse events were observed, none of which were categorized
as serious and most were deemed unrelated to the formulation.
Three subjects experienced gastrointestinal symptoms (nausea,
abdominal pain) that possibly could be related to the for-
mulation. No flushing, a side effect attributed to the nicotinic
acid form of niacin in an older formulation (personal
communication, K. Papas), was observed. No vitamin A level
exceeded the laboratory's reported normal range at any of the
study visits.
At baseline, plasma concentrations of 25-hydroxyvitamin
D, α- and γ-tocopherol, β-carotene, and CoQ10 were higher
whereas PIVKA-II were lower in the PS CF subjects
compared with the PI subjects (Table 3). Daily supplemen-
tation with AquADEKs® significantly increased plasma β-
carotene, CoQ10, and γ-tocopherol and decreased PIVKA-II
levels from baseline to week 12 when examining the entire CF
cohort (Table 3). Supplementation did not significantly
increase plasma 25-hydroxyvitamin D concentrations.
Among the PI subjects, AquADEKs® significantly increased
plasma β-carotene (p=0.001) and reduced PIVKA-II levels
(p=0.004) but did not lead to significant changes in CoQ10
Table 3
Plasma concentrations of vitamins and antioxidants in the pancreatic insufficient
and sufficient CF subjects at baseline, 6 weeks and 12 weeks following
AquADEKs supplementation.
Parameter Baseline 6 weeks 12 weeks
No. of subjects
PI 11 11 11
PS 6 4 4 ⁎⁎
Retinol (μg/dL)
PI 39.0 (32.0–48.0) 43.0 (37.0–45.0) 39.0 (35.0–53.0)
PS 44.0 (43.0–50.0) 50.0 (43.0–56.0) 54.0 (48.5–58.5)
25-OH vitamin D (ng/mL)
PI 21.0 (14.0–30.0) 27.0 (21.0–32.0) 21.0 (17.0–30.0)
PS 31.0 (26.0–33.0) ⁎ 32.0 (25.5–35.0) 34.5 (30.0–37.5)
γ-Tocopherol (μg/mL)
PI b1.0 (b1.0–1.1) 1.2 (b1.0–2.0) b1.0 (b1.0–1.8) §
PS 1.25 (1.2–1.6) ⁎ 1.8 (1.3–4.4) 1.75 (1.1–2.7)
α- Tocopherol (μg/mL)
PI 9.6 (6.5–11.1) 10.9 (9.5–14.8) 11.2 (8.5–13.3)
PS 12.2 (11.4–14.4) ⁎ 18.5 (16.6–22.9) ⁎ 16.4 (13.3–24.4) ⁎
β-Carotene (μg/mL)
PI b0.03 (b0.03–0.05) 0.15 (0.09–0.28) 0.10 (0.05–0.31) ‡
PS 0.22 (0.08–0.67) † 0.78 (0.49–1.05) ⁎ 0.41 (0.20–1.56) ⁎
CoQ10 (μg/mL)
PI 0.33 (0.23–0.39) 0.42 (0.31–0.53) 0.42 (0.33–0.47) §
PS 0.62 (0.56–0.70) † 0.95 (0.70–1.20) † 0.85 (0.70–1.33) †
PIVKA-II (ng/mL)
PI 4.7 (2.4–13.8) 2.0 (2.0–2.3) 2.55 (2.0–6.3) ‡
PS 2.0 (2.0–2.0) † 2.0 (2.0–2.0) 2.0 (2.0–2.0) ⁎
Values are median and interquartile ranges.
PI, pancreatic insufficient; PS, pancreatic sufficient.
⁎⁎ One PS subject discontinued the formulation between visits 2 and 3, but
completed the visit 3 requirements within a week of the recommended visit
date.
⁎ pb0.05 relative to the PI group.
† pb0.01 relative to the PI group.
§ pb0.05 change from baseline, pooled PI and PS subjects.




















Fig. 2. Correlations between changes in β-carotene concentration and BMI
percentiles. Pancreatic sufficient subjects (open circles), pancreatic insufficient
subjects (closed circles).
Fig. 1. Changes in plasma β-carotene, γ-tocopherol, and PIVKA-II levels from
baseline to weeks 6 and 12 in the pancreatic insufficient subjects.
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hydroxyvitamin D (p=0.4) or α-tocopherol (0.58). Changes
in select micronutrient levels in the PI CF subjects are
displayed in Fig. 1.
For the entire CF cohort, there were improvements in clinical
outcomes including weight percentile (+2.4% {IQR: −0.05–
4.5%}; p=0.03) and FEV1 %predicted (+3.8% {IQR: −2.0–
9.1%}; p=0.04) during the intervention period. Changes in
body mass index (BMI) percentile (+2.2% {IQR: −2.0–5.3%};
p=0.17) and urine 8-isoprostane levels (baseline: 1433 pg/mL
(112–3859); 12 weeks: 1266 pg/mL (342–2784); p=0.23)
were not statistically significant. The change in plasma β-
carotene concentrations weakly correlated with the change in
both weight percentile (r=0.51, p=0.04) and BMI percentile
(r=0.63, pb0.01) (Fig. 2), but not FEV1 (r=0.03, p=0.94).
Changes in tocopherols, CoQ10, and 8-isoprostanes did not
correlate with changes in weight, BMI or FEV1.4. Discussion
In this study, a commercially-available antioxidant-rich
multivitamin supplement (AquADEKs®) increased circulating
antioxidant levels and decreased PIVKA-II concentrations,
while maintaining vitamin A levels in the normal range in both
PI and PS CF subjects. Two daily AquADEKs® capsules did
not normalize plasma concentrations of 25-hydroxyvitamin
D and PIVKA-II in all subjects enrolled. Nearly 30% of
participants experienced gastrointestinal symptoms at some
35S.D. Sagel et al. / Journal of Cystic Fibrosis 10 (2011) 31–36point during the study that may have been related in part to this
formulation. Subjects enrolled in this trial experienced modest
improvements in weight and pulmonary function and increased
β-carotene levels were weakly associated with better growth
parameters. Similar to findings in previous studies [9,20], our
PI subjects had lower antioxidant vitamin concentrations than
did PS subjects, suggesting the need for higher antioxidant
vitamin supplementation in PI subjects. At baseline prior to
supplementation, most of the micronutrient and antioxidant
deficiencies were observed almost exclusively in the PI
subjects.
These results are comparable to those seen in previous trials
that have examined supplementation with β-carotene and/or
other antioxidant formulations in CF [4,21–27]. The results of
several of these studies have been previously reviewed [28]. In
these studies, before supplementation, circulating β-carotene
and vitamin E levels were consistently low. Oral treatment was
effective in correcting β-carotene and/or vitamin E concentra-
tions without significant adverse effects. Supplementation has
generally led to decreased levels of lipid peroxidation products
and other markers of oxidative stress [4,23–25]. Two of these
studies reported modest improvements in lung function [26] and
reduced need for antibiotic therapy [4,25], while most of the
others did not find significant differences in clinical outcomes.
The evidence is currently unconvincing that improving plasma
levels of these antioxidant vitamins attenuates pulmonary
deterioration or positively impacts other clinically relevant
outcomes in CF. However, the lack of proof may be due to
limitations of these studies which used different formulations
and generally involved few subjects followed over a relatively
short duration.
In spite of this lack of evidence, there is a strong rationale to
normalize systemic fat-soluble vitamin and antioxidant levels.
Epidemiologic surveys among the general population have
found that higher dietary antioxidant vitamin consumption
(including β-carotene and vitamin E) and/or higher circulating
levels of these antioxidants are associated with better pulmo-
nary function and lower rates of lung function decline [29–31].
Similarly, in CF, correlations between antioxidant concentra-
tions and lung function have been reported [11,26].
AquADEKs® have a number of theoretical advantages
compared to other commercially-available CF vitamin pre-
parations. This formulation utilizes micelle-like particles to
enhance absorption of fat-soluble vitamins and micronutrients
compared with oil-based products [32]. Compared to other CF
multivitamin products, AquADEKs® contain increased
amounts of the antioxidants β-carotene and γ-tocopherol.
This product includes CoQ10, often deficient in children with
CF and related in part to clinical outcomes [9], and selenium, a
cofactor that stimulates endogenous antioxidant enzymes such
as glutathione. AquADEKs® also have higher concentrations
of vitamin K in comparison to other CF multivitamin products.
This may explain why we observed a decrease in PIVKA-II
levels despite the fact that subjects were taking other CF
multivitamin preparations up until the time of the baseline
study visit. Yet, PIVKA-II levels did not normalize in all
subjects and even those who did show an improvement maystill have vitamin K deficiency of the bone. Similarly, despite
taking twice the recommended amount [33] of vitamin D (D3,
cholecalciferol) via two softgel capsules, many of our subjects
still had evidence of vitamin D insufficiency (b30 ng/mL).
Granted, this study was primarily conducted during the winter
and spring months when cutaneous synthesis of vitamin D is
limited and circulating concentrations tend to be lower [7]. But
these results, in combination with other recent studies [6,8,34],
suggest that individual patients will need additional supple-
mentation with vitamins D and K beyond that contained in
2 AquADEKs® capsules to normalize vitamin D and K status
in CF.
The findings in this trial were analogous to our initial pilot
study in which supplementation with a prototype formulation
increased plasma β-carotene, but not retinol concentrations
[16]. Reassuringly, we did not observe elevated retinol levels
even after eliminating an initial wash-out period, extending the
treatment period from 8 to 12 weeks, and enrolling pancreatic
sufficient subjects. We acknowledge that plasma retinol levels
may be better at assessing vitamin A deficiency rather than
excess, and that other circulating markers may be better
indicators of excess states [10]. However, the risk of hyper-
vitaminosis A with chronic supplementation of this formulation
is low because AquADEKs® contain less pre-formed vitamin A
(retinol) than other CF vitamin supplements. β-carotene, as a
provitamin A antioxidant, is subject to strict regulation in
its conversion to vitamin A, and not all gets processed to retinol
[10].Further, long-term supplementation with β-carotene does
not appear to increase retinol levels above the normal range
[4,35].
This study and our previous one [16] were not controlled
clinical trials. These were primarily safety and tolerability
studies, not powered to detect significant changes in lung
function or other clinical outcomes. However, the modest
improvements in weight and pulmonary function in this study
and the small yet significant reductions in airway inflammation
in the former support further clinical study of this formulation.
One disappointing finding was the lack of effect on oxidative
stress. While circulating antioxidant levels improved with
supplementation, there was no corresponding decrease in
urinary 8-isoprostance concentrations. Similar findings have
been previously reported [26]. It is possible that a systemic
measure of oxidative stress (in urine or plasma) is not as
sensitive as directly measuring oxidative stress in the lung or
that the antioxidants in this formulation are not potent enough to
effectively reduce oxidative stress in CF. This will need to be
further assessed in a larger clinical trial.
In summary, daily supplementation of a commercially-available
antioxidant-rich multivitamin supplement (AquADEKs®)
over 12 weeks significantly increased circulating β-carotene
levels and decreased PIVKA-II concentrations in both PI and PS
CF subjects, with a satisfactory safety and tolerability profile over
that period. Modest improvements in weight and pulmonary
function were observed in this trial and augmented β-carotene
levelswere associatedwith enhanced growth.A larger randomized,
placebo-controlled trial should be performed to assess the impact of
improved vitamin and antioxidant status on relevant CF clinical
36 S.D. Sagel et al. / Journal of Cystic Fibrosis 10 (2011) 31–36outcomes including growth, pulmonary function, lung infections
and quality of life.
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